Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

Hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, and severe preeclampsia significantly elevate ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin ...

Hemolysis is your body’s natural process of removing old or dysfunctional red blood cells. Certain health conditions, medications, or recent infections can sometimes cause hemolysis to go into ...

Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (EPA: SASY) (NASDAQ: SNY) to buy the global ...